Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Lymphoid 2Genitourinary 2Breast 2Thoracic 1Plasma cell 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Lymphangioleiomyomatosis 1Erdheim-Chester Disease 1Endocrine Gland Neoplasms 1Castleman Disease 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Temozolomide 31Magnetic Resonance Spectroscopy 31Specimen Handling 18Radiation 13Radiotherapy 12Biopsy 11Bevacizumab 11Nivolumab 9X-Rays 7Radiosurgery 7Nuclear Medicine Department, Hospital 7Carboplatin 7Lomustine 6Cyclophosphamide 6Vincristine 5Phantoms, Imaging 5Cisplatin 5ulixertinib 4trametinib 4pembrolizumab 4erdafitinib 4binimetinib 4abemaciclib 4Irinotecan 4Ipilimumab 4Immunoglobulin G 4Etoposide 4Disulfides 4Aminolevulinic Acid 4AZD 6244 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
temsirolimus × CNS × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡